Posts Tagged ‘Jeff Trewhitt’

California Biopharmaceutical Companies Are Developing Over Two-Fifths of Breakthrough Biotechnology Medicines

Posted: Oct 13, 2011 | Posted by Kassy Perry | No Comments

WASHINGTON — (BUSINESS WIRE) — More than 400 of the record 901 biotechnology medicines in development today are being created by biopharmaceutical companies with major operations in California, a new report shows.

Companies with headquarters there account for 201 of the new-generation drugs.

The report, compiled by the Pharmaceutical Research and Manufacturers of America (PhRMA), finds that California’s biopharmaceutical companies have embraced a variety of new techniques as they develop 92 biotechnology-derived vaccines to both prevent and treat disease, 193 monoclonal antibody treatments, 33 recombinant proteins and other medicines made from cells and genes.

California Companies Target Heart Disease, Cancer With More Than 240 Medicines in Development

Posted: May 23, 2011 | Posted by Kassy Perry | No Comments

WASHINGTON–(BUSINESS WIRE)–At a time when cancer and heart disease are the nation’s and the world’s top killers, biopharmaceutical research companies headquartered in California are developing 243 of the 1,186 medicines in development for those dreaded diseases.

The California companies are developing 188 of 887 drugs for more than 20 types of cancer and 55 of 299 medicines for heart disease and stroke.

The cancer statistics are contained in a new report “Medicines in Development for Cancer” published by the Pharmaceutical Research and Manufacturers of America (PhRMA), while the data on heart disease and stroke are from a PhRMA report from early this year.

The cancer report and “Medicines in Development for Heart Disease and Stroke” can be found on the PhRMA website,